Fig. 2: COVID-19 risk by D29 antibody marker level.
From: Immune correlates analysis of the ENSEMBLE single Ad26.COV2.S dose vaccine efficacy clinical trial
a–c, Plots showing covariate-adjusted cumulative incidence of COVID-19 by Low, Medium or High tertile of D29 antibody marker level in baseline SARS-CoV-2 seronegative per-protocol participants. a, Anti-spike IgG concentration. b, Anti-RBD IgG concentration. c, PsV neutralization ID50 titre. Baseline covariates adjusted for were baseline risk score and geographic region.
